To fight the ever-growing threat from antibiotic-resistant bacteria, Australian researchers developed a therapy containing a repurposed experimental Alzheimer's drug, successfully killing some of the most difficult to treat superbugs.

One of the biggest drug decisions in decades is looming as U.S. regulators consider whether to approve the first medicine that’s claimed to slow mental decline from Alzheimer’s disease, the most common form of dementia.